Equities

ImmuneOnco Biopharmaceuticals Shanghai Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

ImmuneOnco Biopharmaceuticals Shanghai Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)4.58
  • Today's Change0.150 / 3.39%
  • Shares traded860.80k
  • 1 Year change-17.03%
  • Beta--
Data delayed at least 15 minutes, as of Feb 13 2026 08:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

ImmuneOnco Biopharmaceuticals Shanghai Inc is a China-based company mainly engaged in the development of tumor immunotherapy. The Company's main businesses include the development of biotechnology for the systemic utilization of innate and adaptive immunity, and the development of next-generation tumor immunotherapies, which primarily focus on the adaptive immune system. The Company's core product IMM01 is an innovative CD47-targeted molecule. The Company mainly operates its businesses in the domestic and overseas markets.

  • Revenue in HKD (TTM)126.96m
  • Net income in HKD-342.81m
  • Incorporated2015
  • Employees195.00
  • Location
    ImmuneOnco Biopharmaceuticals Shanghai IncSHANGHAI ChinaCHN
  • Phone+86 2 138016387
  • Websitehttp://immuneonco.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sunho Biologics Inc0.00-92.97m1.00bn128.00--1.84-----0.616-0.6160.003.480.00----0.00-14.33---15.84----------6.57--0.1242------39.74------
B&K Corp Ltd295.61k-206.83m1.09bn100.00--11.43--3,701.60-1.76-1.760.00250.8138----------------92.34---69,968.59------0.0371---44.70---101.78------
Brii Biosciences Ltd0.00-425.51m1.13bn96.00--0.3986-----0.5846-0.58460.003.910.00----0.00-14.05-49.92-14.09-54.57-------12,750.27----0.003---100.00---190.66---33.13--
Kintor Pharmaceutical Ltd12.44m-189.22m1.39bn136.00--5.10--111.83-0.4375-0.43750.02880.54670.019410.661.0674,049.78-29.53-47.72-44.54-55.96-55.12-36.16-1,521.00-8,974.730.4222-33.760.2881------85.36---53.11--
Wuhan YZY Biopharma Co Ltd164.23m-88.38m1.40bn106.00------8.55-0.4559-0.45590.8472-0.16040.580511.5413.961,453,323.00-31.24---133.35--63.96---53.82--0.9019-24.381.21------49.09------
HighTide Therapeutics Inc0.00-329.76m1.49bn57.00--3.75-----0.7294-0.72940.000.69420.00----0.00-49.50---63.55--------------0.2129------59.35------
Immunotech Biopharm Ltd0.00-253.13m1.60bn173.00---------0.4523-0.45230.00-0.28820.00----0.00-37.04-36.20-186.73-45.67--------0.0712-6.631.48------44.18--5.95--
Cloudbreak Pharma Inc78.16m-326.97m1.91bn60.00------24.47-0.3898-0.38980.0932-3.08------1,532,549.00-------------418.33------19.44------23.40------
ImmuneOnco Biopharmaceuticls Shanghi Inc126.96m-342.81m1.98bn195.00--3.08--15.57-0.8715-0.87150.32251.490.148--3,865.48813,859.90-40.09---51.56-------270.79------0.2236--19,109.59--16.76------
Mabpharm Ltd480.14m-31.12m2.10bn383.00--18.7856.964.38-0.0076-0.00760.11640.02720.42090.46594.051,524,243.00-2.73-19.62-4.02-25.6986.40---6.48-211.590.6906-1.580.7552--196.27--38.89---12.13--
Jiangsu Recbio Technology Co Ltd12.34m-740.61m2.11bn507.00--10.29--170.98-1.55-1.550.02580.42470.006----23,246.88-36.26-31.31-64.03-37.31-----5,990.59--0.2767-100.740.8254------1.67--16.82--
Frontage Holdings Corp1.98bn29.97m2.20bn1.54k73.110.82376.991.110.01480.01480.97361.310.454560.363.971,267,645.000.69023.050.86543.6427.7832.141.526.841.221.970.28610.00-1.9020.48-92.68-46.7213.29--
Antengene Corp Ltd95.54m-258.90m2.36bn152.00--2.72--24.67-0.4166-0.41660.15381.280.06191.513.20565,309.60-16.77-48.14-19.52-53.0678.54---271.00-1,460.934.41--0.2346--36.62--45.07--259.46--
Hanx Biopharmaceuticals (Wuhan) Co Ltd-100.00bn-100.00bn2.61bn-------------------------------------------------------52.30------
Clover Biopharmaceuticals Ltd58.64m-1.03bn2.86bn243.00------48.70-0.8203-0.82030.0466-1.490.04330.054747.89195,458.50-76.07-75.37---188.1462.57---1,756.85-13,419.000.2541-------2.13---552.11---24.90--
Data as of Feb 13 2026. Currency figures normalised to ImmuneOnco Biopharmaceuticals Shanghai Inc's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

2.00%Per cent of shares held by top holders
HolderShares% Held
GF Fund Management Co., Ltd.as of 30 Jun 20253.28m0.78%
E Fund Management Co., Ltd.as of 30 Jun 20251.78m0.42%
Manulife Investment Management (Hong Kong) Ltd.as of 30 Jun 20251.15m0.27%
SSgA Funds Management, Inc.as of 08 Jan 2026948.20k0.23%
HuaAn Fund Management Co., Ltd.as of 30 Jun 2025405.00k0.10%
Zhong Ou Asset Management Co., Ltdas of 30 Jun 2025399.00k0.10%
China Universal Asset Management Co., Ltd.as of 30 Jun 2025282.40k0.07%
ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025100.00k0.02%
Truvalue Asset Management Co. Ltd.as of 30 Jun 202584.00k0.02%
Golden Trust Sinopac Fund Management Co., Ltd.as of 30 Jun 20250.000.00%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.